[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578391":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":34,"responsibleParty":54,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Atlantic Health System","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Methenamine prophylaxis","EXPERIMENTAL","Methenamine will be prescribed for urinary tract infection prophylaxis",[13],"Drug: Methenamine Hippurate 1g BD",{"label":15,"type":16,"description":17,"interventionNames":18},"Antibiotic prophylaxis","ACTIVE_COMPARATOR","Antibiotic prophylaxis chosen per physician preference",[19],"Other: Antibiotic prophylaxis",[21,26],{"type":22,"name":23,"description":15,"armGroupLabels":24,"otherNames":25},"DRUG","Methenamine Hippurate 1g BD",[9],null,{"type":6,"name":15,"description":15,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Rena Ow, MD","CONTACT","9739717267","rena.ow@atlantichealth.org",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Atlantic Health","RECRUITING","Morristown","New Jersey","07928","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-74.48154,40.79677,{"lat":47,"lon":46},[50,51],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Shaun Adair, MD","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Shaun Adair","MD","100578391","is-methenamine-prophylaxis-for-urinary-tract-infection-after-midurethral-sling-as-effective-as-antibiotic-prophylaxis-100578391",false,"NCT06810687","Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis?","Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis? A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female\n2. Age ≥ 18\n3. Patients undergoing mid-urethral sling procedure\n\nExclusion Criteria:\n\n1. Medication intolerance or allergy to study medications\n2. Renal impairment with GFR \\\u003C30\n3. Breast feeding\n4. Pregnancy\n5. Recurrent urinary tract infections\n6. Active urinary tract infection\n7. Immunosuppressive disease\n8. Interstitial cystitis",true,"FEMALE","18 Years","100 Years",{"count":69,"type":70},190,"ESTIMATED","INTERVENTIONAL",[73],"NA","Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%.\n\nPost-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI.\n\nThe investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.",[76],"Urinary Tract Infection (Diagnosis)",[78,79,80,81],"urinary tract infection","midurethral sling","prophylaxis","methenamine","2025-02-05",{"date":84,"type":85},"2025-02-07","ACTUAL",{"date":87,"type":85},"2025-01-30",{"date":89,"type":70},"2028-01-30",{"name":5,"class":6},1]